NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/21/2025
Back to search
Official data from USPTO
BIOTHERYX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
01/21/2025
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
08/23/2021
Registration date
01/21/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2025
Last transaction
01/21/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/19/2024
First use in commerce
08/19/2024
Drawing code
4
Owner type
03
Owner location
San Diego, CA, US
Examiner
NOVAKOVIC, MIROSLAV
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BioTheryX, Inc.
Representatives
Stacey R. Halpern KNOBBE, MARTENS, OLSON & BEAR, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicalbiological and pharmaceutical preparations for scientificresearchmedical or pharmaceutical usepharmaceutical preparations for restoring protein levels to treat diseases related to aberrant protein expression; none of the foregoing being pharmaceutical preparations for the treatment of anthraxanthrax vaccinesvaccines
Publications
History of USPTO decisions and trademark events.
34 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/30/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/30/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/25/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/25/2024
IUAF
USE AMENDMENT FILED
08/21/2024
EISU
TEAS STATEMENT OF USE RECEIVED
08/21/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/15/2024
EX2G
SOU EXTENSION 2 GRANTED
02/14/2024
EXT2
SOU EXTENSION 2 FILED
02/14/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/14/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/17/2023
EX1G
SOU EXTENSION 1 GRANTED
08/15/2023
EXT1
SOU EXTENSION 1 FILED
08/15/2023
EEXT
SOU TEAS EXTENSION RECEIVED
08/15/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/21/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/06/2023
CHPB
POST PUBLICATION AMENDMENT - ENTERED
10/26/2022
APET
ASSIGNED TO PETITION STAFF
10/26/2022
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
10/21/2022
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
07/27/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/28/2022
PUBO
PUBLISHED FOR OPPOSITION
06/28/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/25/2022
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
05/25/2022
DOCK
ASSIGNED TO EXAMINER
05/25/2022
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
04/07/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/08/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/08/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/08/2021
NWAP
NEW APPLICATION ENTERED
08/26/2021
Continuous trademark protection
Get notified about every new filing that threatens BIOTHERYX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.